Edition:
India

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

2.93USD
19 Jan 2018
Change (% chg)

$0.16 (+5.78%)
Prev Close
$2.77
Open
$2.80
Day's High
$3.03
Day's Low
$2.78
Volume
442,851
Avg. Vol
347,808
52-wk High
$4.24
52-wk Low
$0.50

Chart for

About

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI)... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $454.30
Shares Outstanding(Mil.): 118.31
Dividend: --
Yield (%): --

Financials

BRIEF-Aveo Pharma Entered Into Binding MoU With Class Representatives Regarding Settlement Of A 2013 Class Action Lawsuit

* AVEO PHARMACEUTICALS - ENTERED INTO BINDING MOU WITH CLASS REPRESENTATIVES BOB LEVINE & WILLIAM WINDHAM REGARDING SETTLEMENT OF A 2013 CLASS ACTION LAWSUIT

27 Dec 2017

BRIEF-Aveo Oncology Announces Clinical Updates To Tivozanib And Ficlatuzumab Programs

* AVEO ONCOLOGY ANNOUNCES CLINICAL UPDATES TO TIVOZANIB AND FICLATUZUMAB PROGRAMS

07 Dec 2017

BRIEF-Aveo Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln

* AVEO PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING Source text: [http://bit.ly/2Bzw8T1] Further company coverage:

01 Dec 2017

BRIEF-AVEO PHARMACEUTICALS REPORTS Q3 LOSS PER SHARE $0.22

* AVEO REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

07 Nov 2017

BRIEF-Aveo Pharmaceuticals- Tivo-3 study will continue as planned without modification

* Aveo Pharmaceuticals Inc - ‍announces completion of Tivo-3 study futility analysis with no changes to study protocol​

06 Oct 2017

BRIEF-AVEO Oncology and EUSA Pharma announce TiNivo combination study opt-in

* Aveo Pharmaceuticals Inc - ‍EUSA Pharma has agreed to pay AVEO up to $388 million in future milestone payments and research and development funding​

20 Sep 2017

BRIEF-Aveo Oncology announces Fotivda approved in the EU for the treatment of advanced renal cell carcinoma

* Aveo Oncology announces Fotivda® (tivozanib) approved in the European Union for the treatment of advanced renal cell carcinoma

28 Aug 2017

BRIEF-Aveo Pharmaceuticals Inc Q2 loss per share $0.30

* Aveo reports second quarter 2017 financial results and provides business update

09 Aug 2017

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥3,468 +165.00
Eisai Co., Ltd (4523.T) ¥6,337 +59.00
Pfizer Inc. (PFE.N) $36.94 -0.05
Novartis AG (NOVN.S) CHF83.20 -0.18
Roche Holding Ltd. (ROG.S) CHF236.10 +1.60
Roche Holding Ltd. (RO.S) CHF239.20 +1.40
Bayer AG (BAYGn.DE) €104.08 --
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €70.93 -2.02
AstraZeneca plc (AZN.L) 5,043.00 --

Earnings vs. Estimates